2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. VEGFR
  5. VEGFR Isoform
  6. VEGFR Inhibitor

VEGFR Inhibitor

VEGFR Inhibitors (343):

Cat. No. 상품명 효과 Purity
  • HY-P990541
    Anti-VEGFR1/FLT1 Antibody
    		Inhibitor
    Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-10330S
    Toceranib-d8
    		Inhibitor 99.08%
    Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors.
  • HY-10260S1
    Vandetanib-d4
    		Inhibitor
    Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM).
  • HY-173124
    CDK2/FLT4/PDGFRA-IN-1
    		Inhibitor
    CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells.
  • HY-160685
    GW809897X
    		Inhibitor
    GW809897X is a dual inhibitor of Fluc and VEGFR with IC50 of 0.58 μM and 65 nM, respectively. GW809897X is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential impact on Fluc reporter assays.
  • HY-177612B
    AGN-745 sodium scrambled negative control
    		Inhibitor
    AGN-745 sodium scrambled negative control is the sequence scrambled negative control of AGN-745 sodium.
  • HY-P991132
    Efclarofusp alfa
    		Inhibitor
    Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor.
  • HY-139822
    VEGFR-2-IN-10
    		Inhibitor
    VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC50 = 0.7 μM) against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.
  • HY-116452
    YLT192
    		Inhibitor
    YLT192 is an orally active and highly bioavailable VEGFR2 inhibitor with potent anti-angiogenic activity and anti-tumor efficacy. YLT192 significantly inhibited the kinase activity of VEGFR2 and inhibited the proliferation, migration, invasion and tube formation of human umbilical cord vascular endothelial cells. YLT192 also inhibited VEGF-induced VEGFR2 phosphorylation and its downstream signaling regulators. YLT192 also showed the ability to inhibit angiogenesis in vivo in zebrafish embryo models and alginate-coated tumor cell experiments. YLT192 can directly inhibit the proliferation of cancer cells and induce their apoptosis.
  • HY-18333
    EG00229
    		Inhibitor
    EG00229 is an inhibitor for VEGF-A and NRP1 interaction with an IC50 of 8 μM. EG00229 inhibits the migration of HUVECS and the phosphorylation of VEGFR2 in endothelial cells. EG00229 exhibits cytotoxicity in cancer cell A549.
  • HY-P991419
    MSB-0254
    		Inhibitor
    MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research.
  • HY-168127
    VEGFR-2-IN-57
    		Inhibitor
    VEGFR-2-IN-57 (compound 6n) exhibited significant cytotoxicity in HUVEC cells (IC50 = 28.77 nM).
  • HY-P991418
    MW02
    		Inhibitor
    MW02 is a human monoclonal antibody (mAb) targeting VEGFA. MW02 can be used in Wet age-related macular degeneration research.
  • HY-139996
    Pomalidomide-C5-Dovitinib
    		Inhibitor
    Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD+ acute myeloid leukemia.
  • HY-P992511
    CS2009
    		Inhibitor
    CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. CS2009 blocks the interactions of PD-1/PD-L1, CTLA-4/CD80 and VEGFA/VEGFR2, mediates checkpoint inhibition, and suppresses tumor angiogenesis. CS2009 reactivates PD-1/CTLA-4 double-positive tumor-infiltrating T lymphocytes, induces T cell activation, enhances tumor growth inhibition, promotes vascular normalization, improves T lymphocyte infiltration, and converts the immunosuppressive tumor microenvironment into an immunocompetent one. CS2009 can be used for the research of various advanced solid tumors.
  • HY-168279
    VEGF-IN-1
    		Inhibitor
    VEGF-IN-1 (compound 6) can reduce the release of VEGF in U87-MG cells and inhibit angiogenesis in vitro. VEGF-IN-1 can inhibit cell proliferation by inducing autophagy in tumor cells, with an IC50 value of 28.35 μM for U87-MG cells.
  • HY-13590
    CEP-7055
    		Inhibitor
    CEP-7055 (compound 21) is a novel vascular endothelial growth factor R2 (VEGF-R2) tyrosine kinase inhibitor with potent inhibitory activity. Studies have found that the inhibitor activity can be significantly improved by optimizing the R9 substituent. Compound 21 has potent low nanomolar inhibition of human VEGF-R tyrosine kinase and shows good selectivity against multiple tyrosine and serine/threonine kinases. N,N-dimethylglycine ester 40 was prepared to improve its water solubility and oral bioavailability. In animal pharmacokinetic studies, a significant increase in the plasma level of 21 was observed after oral administration of 40. Compound 21 showed significant in vivo antitumor activity in multiple tumor models and has entered phase I clinical trials as a water-soluble N,N-dimethylglycine ester proagent of 40 (CEP-7055).
  • HY-W342441
    Monosialoganglioside GM3 (bovine)
    		Inhibitor
    Monosialoganglioside GM3 (bovine) is a monosialoganglioside and an inhibitor of VEGFR2 and Akt. At a concentration of 20 μM, Monosialoganglioside GM3 inhibits angiogenesis and reduces the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by inhibiting VEGFR2 and Akt phosphorylation. Ganglioside GM3 also inhibits ferroptosis, providing protective effects during the formation of abdominal aortic aneurysms. Additionally, Monosialoganglioside GM3 (bovine) acts as an inhibitor of insulin signaling, inducing the dissociation of the insulin receptor (IR)-Caveolin-1 complex from lipid microdomains and causing insulin resistance in adipocytes. Monosialoganglioside GM3 (bovine) can be used in cancer and metabolic disease research.
  • HY-163533
    CPD-002
    		Inhibitor
    CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis.
  • HY-160684
    GW701427A
    		Inhibitor
    GW701427A is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.12 μM and 603 nM, respectively. GW701427A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays.